When would you consider switching from standard calcium replacement therapy to the newly approved Encaleret therapy for treatment of hypocalcemia secondary to hypoparathyroidism?

Encaleret at this time is not used to treat other hypocalcemic disorders other than autosomal dominant hypocalcemia type I (ADH 1). This genetic disorder is caused by a specific genetic gain-of-function mutation in the CASR gene that tricks the body into sensing that calcium levels are too high, even when they are dangerously low. This medication acts as a negative allosteric modulator that specifically binds to and resets overactive calcium-sensing receptors. Studies are underway to determine i...